Management of radiation-induced nausea and vomiting with palonosetron in patients with pre-existing emesis: a pilot study | Zendy

Vithusha Ganesh | Zendy; Stephanie Chan | Zendy; Liying Zhang | Zendy; Leah Drost | Zendy; Carlo DeAngelis | Zendy; Bo Wan | Zendy; Mark Pasetka | Zendy; May Tsao | Zendy; Elizabeth Barnes | Zendy; Natalie Pulenzas | Zendy; Hans T. Chung | Zendy; Pearl Zaki | Zendy; Caitlin Yee | Zendy; Edward Chow | Zendy

Open Access

Management of radiation-induced nausea and vomiting with palonosetron in patients with pre-existing emesis: a pilot study

Author(s) -

Vithusha Ganesh,

Stephanie Chan,

Liying Zhang,

Leah Drost,

Carlo DeAngelis,

Bo Wan,

Mark Pasetka,

May Tsao,

Elizabeth Barnes,

Natalie Pulenzas,

Hans T. Chung,

Pearl Zaki,

Caitlin Yee,

Edward Chow

Publication year - 2018

Publication title -

annals of palliative medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.546

H-Index - 19

eISSN - 2224-5839

pISSN - 2224-5820

DOI - 10.21037/apm.2018.05.10

Subject(s) - nausea , palonosetron , vomiting , medicine , anesthesia , palliative care , chemotherapy , antiemetic , nursing

Approved almost 15 years ago for use in the chemotherapy setting, palonosetron, a 2nd generation 5-hydroxtryptamine 3 receptor antagonist (5-HT3 RA), has demonstrated efficacy in preventing chemotherapy-induced nausea and vomiting. However, its utility in the prophylaxis and treatment of radiation-induced nausea and vomiting (RINV) has yet to be evaluated. In this pilot study, we investigated the rates of control in RINV in patients with pre-existing emesis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research